SYBX - SYNLOGIC, INC.
Previous close
1.59
0.150 9.434%
Share volume: 0
Last Updated: Thu 26 Dec 2024 08:25:25 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.44
0.15
10.42%
Fundamental analysis
18%
Profitability
0%
Dept financing
10%
Liquidity
66%
Performance
25%
Performance
5 Days
0.60%
1 Month
-0.71%
3 Months
-9.15%
6 Months
-8.55%
1 Year
-64.08%
2 Year
98.60%
Key data
Stock price
$1.59
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.39 - $5.12
52 WEEK CHANGE
-$59.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Aoife M. Brennan
Region: US
Website: synlogictx.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: synlogictx.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria and homocystinuria. The company is also developing SYNB1891 that is in Phase I clinical trial to treat solid tumors and lymphoma.
Recent news